CSL Limted (CSL)
CSL Limited on the ASX Stock Exchange
Access the latest stock market reports on CSL Limited (CSL) at the bottom of the page.
Is it time to Buy, Sell or Hold CSL Limited Stocks?
CSL Limited is one of the world's largest suppliers of blood products and vaccines with
operations covering plasma services, biosciences, pharmaceuticals and human vaccines. The major areas of business
operations for CSL are:
CSL Bioplasma &
CSL biotherapies manufactures and markets biological products for human use along with various
prescription pharmaceuticals to treat a multitude of human medical ailments both in Australia and abroad.
CSL bioplasma concentrates its business efforts on treating bleeding disorders like haemophilia,
infections and autoimmune diseases, treating blood disorders among newborns and specialises in the treatment
of severe blood loss and acute burns.
CSL Behring covers a wide range of beneficial services relating to plasma derived products that
are truly life-saving. CSL behring treats people with haemophilia and similar bleeding disorders, immune deficiency
disorders, the prevention of haemolytic diseases in newborns, cardiac surgery patients and shock and burn
CSL Limited Quick Facts (as of Jan 2012)
- Managing Director/CEO: Dr Brian A McNamee
- Chairman: Miss Elizabeth Anne Alexander
- Industry Group: Pharmaceuticals, Biotechnology & Life Sciences
- Shares on issue: 519,894,533
- Market Cap: $16,492,493,866